p53 protein expression in a population-based series of primary vulval squamous cell carcinoma and immediate adjacent field change

Gynecologic Oncology

Volumn 67, Issue 3, 1997, Pages 248-254

  McConnell, Dynes T ^a   Miller, Iain D ^b   Parkin, David E ^a   Murray, Graeme I ^b  

^a DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA;

EID: 19244382338     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4862     Document Type: Article

References (22)

1. 1. Williamson KM, Ireland D: Conservative management of vulvar cancer. Curr Obstet Gynaecol 6:220-225, 1996
2. 2. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R: Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group Study). Gynecol Oncol 49(3):279-283, 1993
3. 3. Van der Velden J, Hacker NF: Prognostic factors in squamous cell cancer of the vulva and the implications for treatment. Curr Opin Obstet Gynecol 8(1):3-7, 1996
4. 4. Jones RW, Rowan DM: Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstet Gynecol 84(5):741-745, 1994
5. 5. Herod JJ, Shafi MI, Rollason TP, Jordan JA, Luesley DM: Vulvar intraepithelial neoplasia: long term follow-up of treated and untreated women. Br J Obstet Gynaecol 103(5):446-452, 1996
6. 6. IARC working group in the evaluation of carcinogenic risks to humans: Human Papillomaviruses, in Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France, International Agency for Research on Cancer (IARC), 1995, Vol 64, p 108
7. 7. MacLean AB: Precursors of vulval cancers. Curr Obstet Gynaecol 3(3): 149-156, 1993
8. 8. Nadal A, Campo E, Pinto J, Mallofre C, Palacin A, Arias C, Traserra J, Cardesa A: p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. J Pathol 175:181-188, 1995
9. 9. Field JK, Spandidos DA, Malliri A, Gosney JR, Yiagnisis M, Stell PM: Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 64:573-577, 1991
10. 10. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the tumour supressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54(18):4855-4878, 1994
11. 11. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Ebv YJ, Ruppert JM, Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53(19): 4477-80, 1993
12. 12. McConnell DT, Wilson BJ, Russell D, Parkin DE, Kitchener HC: Rising incidence of vulval cancer within north east Scotland 1974-1994: a population study. Int J Gynecol Cancer 6:309-312, 1996
13. 13. Wilkinson EJ: Premalignant and Malignant Tumours of the Vulva, in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract, Berlin/New York, Springer-Verlag, 1994, pp 94-95
14. 14. Ridley CM, Frankman O, Jones ISC, Pingus SH, Wilkinson EJ, Fox H, Friedrich EG Jr, Kaufman RH, Lynch PJ: New nomenclature for vulvar disease: International Society for the Study of Vulvar Disease. Human Pathol 20(5):495-496, 1989 [letter]
15. 15. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T: Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 63(5):639-645, 1995
16. 16. Pilotti S, D'Amato L, Della Torre G, Donghi R, Longoni A, Giarola M, Sampietro G, De Palo G, Pierotti MA, Rilke F: Papillomavirus, p53 alteration, and primary carcinoma of the vulva. Diagn Mol Pathol 4(4): 239-248, 1995
17. 17. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R: Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 164(4):997-1004, 1991
18. 18. Landoni F, Maneo A, Zanetta G, Colombo A, Nava S, Placa F, Tancini G, Mangioni C: Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol 61(3): 321-7, 1996
19. 19. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898, 1996
20. 20. Wu SG, El-Deiry WS: p53 and chemosensitivity. Nature Med 2:255-256, 1996
21. 21. Lee JM, Bernstein A: p53 mutations increase resistance to ionising radiation. Proc Natl Acad Sci USA 90:5742-46, 1993
22. 22. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyne K, Shin HJ, Ro JY, Goepfert H, Hong WK, Hittelman WN: p53 expressions: predicting recurrence and second primary tumours in head and neck squamous cell carcinoma. J Natl Cancer Inst 88(8):519-529, 1996